BACK

Circulating Microvesicles Demonstrate Promise for Cancer Testing

Three Posters on Novel Technology Presented at American Association for Cancer Research (AACR)
IRVING, TX, April 4th, 2012 — Caris Life Sciences, a leading biosciences company focused on enabling precise and personalized healthcare through molecular profiling and blood-based diagnostic services, this weekend presented novel findings regarding the biological role of circulating microvesicles (cMV) in the transport and exchange of miRNA, as well as their potential utility as a non-invasive blood-based diagnostic tool, at the American Association for Cancer Research (AACR) annual meeting in Chicago, IL. The data presented further supports the potential of cMV for various blood-based cancer tests, including cancer detection, prognosis and therapeutic response measurement.
A summary of the AACR posters presented follows:
“Differential protein expression and miRNA content of sorted subsets of circulating microvesicles from cancer patients and healthy controls” and “GW182 associates with circulating microvesicles and microRNA in human plasma” support the hypothesis that circulating microvesicles (cMV) are essential components of any blood-based analysis of miRNA. These findings may have a significant impact on the way we think about and analyze miRNA in the future.
“A novel blood-based method for evaluating KRAS in circulating microvesicles from colorectal cancer patients” highlights the clinical potential of detecting therapeutically relevant mutations through the blood-based analysis of cMV.
“With our continuing research on circulating microvesicles, we are learning a tremendous amount about their biology, as well as their clinical and diagnostic potential,” commented David Spetzler, MS, MBA, PhD, Vice President of Discovery Research for Caris Life Sciences. “Our Carisome™ platform has the potential to identify disease-associated circulating microvesicles, showing promise for clinical utility in early diagnostic testing, disease monitoring, and prediction of therapeutic response.”
Caris Life Sciences’ Carisome cMV technology represents the potential to transform healthcare with blood-based diagnostics that may aid clinicians and their patients with treatment decisions. Caris’ work in this area includes major advances in the understanding of cMV and their potential application to patient care, through more accurate diagnosis and therapeutic planning.
About Caris Life Sciences
Caris Life Sciences is a leading biosciences company focused on developing and delivering innovative molecular diagnostic, prognostic and theranostic services. The company’s evidence-based molecular profiling service, Caris Target Now™, matches molecular data generated from a patient’s tumor with biomarker/drug associations derived from the world’s leading clinical cancer literature. Caris Target Now uses the most advanced and clinically-relevant technologies to provide physicians with information to aid in the selection of personalized cancer treatments more likely to work for each patient. Caris is also developing a series of blood tests based on the company’s patented Carisome™ platform — a proprietary, blood-based testing technology for diagnosis, prognosis and theranosis of cancer and other complex diseases. Through the precise and personalized information provided by technologies like Caris Target Now and Carisome, the company believes that the quality of healthcare can be dramatically improved, while also significantly reducing costs. Headquartered in the Dallas metroplex, Caris Life Sciences offers services throughout the United States, Europe and other international markets. To learn more, please visit www.carislifesciences.com or www.caristargetnow.com.
####
Media Inquiries:
Holly Clark
214-596-7060
hclark@carisls.com